Trial Outcomes & Findings for Treatment of Androgenetic Alopecia in Females, 12 Beam (NCT NCT01016964)

NCT ID: NCT01016964

Last Updated: 2012-09-07

Results Overview

The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

63 participants

Primary outcome timeframe

Baseline, 16 weeks, 26 weeks

Results posted on

2012-09-07

Participant Flow

This double-blind, device controlled 26 week study was recruited at 3 clinical study sites. The recruitment period was from February 1, 2010 to September 28, 2010

Key exclusion criteria was pregnancy, malignancy in target area, an no hair transplants, scalp reductions, or hair weaves. Active hair loss less than 12 months.

Participant milestones

Participant milestones
Measure
Sham Device
Sham device
LLT Device 2009 12 Beams
HairMax LaserComb 2009 model 12 beam
Overall Study
STARTED
21
42
Overall Study
COMPLETED
18
39
Overall Study
NOT COMPLETED
3
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Sham Device
Sham device
LLT Device 2009 12 Beams
HairMax LaserComb 2009 model 12 beam
Overall Study
Lost to Follow-up
3
3

Baseline Characteristics

Treatment of Androgenetic Alopecia in Females, 12 Beam

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sham Device
n=21 Participants
Sham device
LLT Device 2009 12 Beams
n=42 Participants
HairMax LaserComb 2009 model 12 beam
Total
n=63 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=93 Participants
0 Participants
n=4 Participants
0 Participants
n=27 Participants
Age, Categorical
Between 18 and 65 years
21 Participants
n=93 Participants
42 Participants
n=4 Participants
63 Participants
n=27 Participants
Age, Categorical
>=65 years
0 Participants
n=93 Participants
0 Participants
n=4 Participants
0 Participants
n=27 Participants
Sex: Female, Male
Female
21 Participants
n=93 Participants
42 Participants
n=4 Participants
63 Participants
n=27 Participants
Sex: Female, Male
Male
0 Participants
n=93 Participants
0 Participants
n=4 Participants
0 Participants
n=27 Participants

PRIMARY outcome

Timeframe: Baseline, 16 weeks, 26 weeks

The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.

Outcome measures

Outcome measures
Measure
Sham Device
n=18 Participants
This control device emits white light
LLT Device 2009 12 Beams
n=39 Participants
This is the active LLLT device
Change in Hair Count at 16 and 26 Weeks Over Baseline
Change at 16 weeks
-0.8 hairs per cm^2
Standard Deviation 7.87
12.5 hairs per cm^2
Standard Deviation 11.35
Change in Hair Count at 16 and 26 Weeks Over Baseline
Change at 26 weeks
3.0 hairs per cm^2
Standard Deviation 9.33
20.6 hairs per cm^2
Standard Deviation 11.55

Adverse Events

Sham Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

LLT Device 2009 12 Beams

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David Michaels

Lexington International, LLC

Phone: 5614170200

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place